Evolus (NASDAQ:EOLS) Earns “Buy” Rating from HC Wainwright

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $27.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 92.58% from the stock’s current price. HC Wainwright also issued estimates for Evolus’ FY2029 earnings at $4.43 EPS.

Separately, Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Tuesday.

Evolus Stock Down 0.8 %

NASDAQ:EOLS opened at $14.02 on Wednesday. Evolus has a twelve month low of $9.25 and a twelve month high of $17.82. The company has a market cap of $887.75 million, a price-to-earnings ratio of -15.41 and a beta of 1.32. The stock has a fifty day simple moving average of $11.75 and a 200-day simple moving average of $13.75. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Institutional Trading of Evolus

Several institutional investors and hedge funds have recently made changes to their positions in the company. Essex Investment Management Co. LLC raised its holdings in shares of Evolus by 0.4% in the third quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company’s stock valued at $4,788,000 after acquiring an additional 1,111 shares in the last quarter. Creative Planning raised its holdings in Evolus by 23.7% in the third quarter. Creative Planning now owns 15,451 shares of the company’s stock worth $250,000 after purchasing an additional 2,963 shares in the last quarter. Sei Investments Co. raised its holdings in Evolus by 9.8% in the second quarter. Sei Investments Co. now owns 33,802 shares of the company’s stock worth $367,000 after purchasing an additional 3,020 shares in the last quarter. KBC Group NV bought a new position in Evolus in the fourth quarter worth about $49,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Evolus by 65.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company’s stock worth $197,000 after purchasing an additional 4,780 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.